Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2007-07-03
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S252160
Reexamination Certificate
active
10560116
ABSTRACT:
The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental.
REFERENCES:
patent: 5891844 (1999-04-01), Häfner
patent: 1 223 170 (2002-07-01), None
patent: 96/09831 (1996-04-01), None
patent: 98/35683 (1998-08-01), None
patent: 99/66926 (1999-12-01), None
patent: 00/27360 (2000-05-01), None
patent: 01/58423 (2001-08-01), None
patent: WO 01/76619 (2001-10-01), None
patent: 03/011316 (2003-02-01), None
Wilkins P. A. et al., “Acute Respiratory Failure:Diagnosis, Monitoring Techniques, and Therapeutics”, Mar. 2003, Clinical Techniques in Equine Practice, vol. 2:56-66.
Bernard, G.R., et al., “Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination”,Intensive Care Med, vol. 20, pp. 225-232, (1994).
Ghofrani, H.A., et al., “Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial”,The Lancet, vol. 360, pp. 895-900, (2002).
Griese, M., “Pulmonary surfactant in health and human lung diseases: state of the art”,Eur Respir J, vol. 13, pp. 1455-1476, (1999).
Hohlfeld, J., et al., “The role of pulmonary surfactant in obstructive airways disease”,Eur Respir J, vol. 10, pp. 482-491, (1997).
Lewis, J.F., et al., “Role of exogenous surfactant in acute lung injury”,Crit Care Med, vol. 31, No. 4, pp. S324-S328, (2003).
Santos, S., et al., “Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD”,Eur Respir J, vol. 19, pp. 632-638, (2002).
Suttorp, N., et al., “Phosphodiesterasen-Inhibition und pulmonale Strombahn—ein neuer Therapieansatz?”,Atemwegs und Lungenkrankheiten,, vol. 22, pp. 560-566, (1996). (ABSTRACT).
Twohig, H.J., et al., “Sildenafil Decreases Arterial Oxygen Levels in Patients with Chronic Obstructive Pulmonary Disease”,Thorax, vol. 55, pp. A40, (2000).
Walmrath, D., et al., “Bronchoscopic Surfactant Administration in Patients with Severe Adult Respiratory Distress Syndrome and Sepsis”,Am J Respir Care Med, vol. 154, pp. 57-62, (1996).
Zhao, L., et al., “Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension”,Circulation, vol. 104, pp. 424-428, (2001).
Altana Pharma AG
Goldberg Joshua B.
Khanna Hemant
McGee Sheldon M.
The Nath Law Group
LandOfFree
Composition comprising a pulmonary surfactant and a PDE5... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising a pulmonary surfactant and a PDE5..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising a pulmonary surfactant and a PDE5... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792803